Please use this identifier to cite or link to this item:
https://hdl.handle.net/10356/87984
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chalmers, James D | en |
dc.contributor.author | Chotirmall, Sanjay Haresh | en |
dc.date.accessioned | 2018-03-05T08:53:42Z | en |
dc.date.accessioned | 2019-12-06T16:53:30Z | - |
dc.date.available | 2018-03-05T08:53:42Z | en |
dc.date.available | 2019-12-06T16:53:30Z | - |
dc.date.issued | 2018 | en |
dc.identifier.citation | Chalmers, J. D., & Chotirmall, S. H. (2018). Bronchiectasis: new therapies and new perspectives. The Lancet Respiratory Medicine, in press. | en |
dc.identifier.issn | 2213-2600 | en |
dc.identifier.uri | https://hdl.handle.net/10356/87984 | - |
dc.description.abstract | European Respiratory Society guidelines for the management of adult bronchiectasis highlight the paucity of treatment options available for patients with this disorder. No treatments have been licensed by regulatory agencies worldwide, and most therapies used in clinical practice are based on very little evidence. Development of new treatments is needed urgently. We did a systematic review of scientific literature and clinical trial registries to identify agents in early-to-late clinical development for bronchiectasis in adults. In this Review, we discuss the mechanisms and potential roles of emerging therapies, including drugs that target airway and systemic inflammation, mucociliary clearance, and epithelial dysfunction. To ensure these treatments achieve success in randomised clinical trials-and therefore reach patients-we propose a reassessment of the current approach to bronchiectasis. Although understanding of the pathophysiology of bronchiectasis is at an early stage, we argue that bronchiectasis is a heterogeneous disease with many different biological mechanisms that drive disease progression (endotypes), and therefore the so-called treatable traits approach used in asthma and chronic obstructive pulmonary disease could be applied to bronchiectasis, with future trials targeted at the specific disease subgroups most likely to benefit. | en |
dc.language.iso | en | en |
dc.relation.ispartofseries | The Lancet Respiratory Medicine | en |
dc.rights | © 2018 Elsevier Ltd. | en |
dc.subject | Therapies | en |
dc.subject | Bronchiectasis | en |
dc.title | Bronchiectasis: new therapies and new perspectives | en |
dc.type | Journal Article | en |
dc.contributor.school | Lee Kong Chian School of Medicine (LKCMedicine) | en |
dc.identifier.doi | 10.1016/S2213-2600(18)30053-5 | en |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
Appears in Collections: | LKCMedicine Journal Articles |
SCOPUSTM
Citations
5
132
Updated on Mar 21, 2024
Web of ScienceTM
Citations
5
124
Updated on Oct 31, 2023
Page view(s) 50
466
Updated on Mar 27, 2024
Google ScholarTM
Check
Altmetric
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.